Urinary gonadotropin peptide (UGP) as a marker of gynecologic malignancies

R. Walker, V. Crebbin, J. Stern, Sidney A Scudder, P. Schwartz

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Urinary gonadotropin peptide (UGP) was measured in 866 urines from normal women and women with benign and malignant gynecologic disease using the Triton UGP enzyme immunoassay. The greatest level of overexpression of the marker was observed in patients with ovarian cancer. Using a cutoff of 4 fmol/mg creatinine, UGP was overexpressed in samples from 2% of normal premenopausal women, 15% of normal postmenopausal women, 5% of women with benign gynecologic disease, and 59% of women with ovarian cancer. UGP expression was independent of the histologic type of ovarian cancer. The expression of UGP and CA 125 were not correlated and use of the two markers in tandem increased the sensitivity of detection of disease by greater than 20% over that which was observed using each marker individually. UGP levels were correlated with clinical status, and doubled in value in 67% of patients with progressive disease, and were halved in 93% of patients who were in remission at the time of the study.

Original languageEnglish (US)
Pages (from-to)1703-1709
Number of pages7
JournalAnticancer Research
Volume14
Issue number5 A
StatePublished - 1994
Externally publishedYes

Fingerprint

Female Genital Diseases
Ovarian Neoplasms
Neoplasms
Time and Motion Studies
Immunoenzyme Techniques
urinary gonadotropin fragment
Creatinine
Urine

Keywords

  • CA 125
  • Ovarian cancer
  • Tumor marker
  • UGP
  • Urine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Walker, R., Crebbin, V., Stern, J., Scudder, S. A., & Schwartz, P. (1994). Urinary gonadotropin peptide (UGP) as a marker of gynecologic malignancies. Anticancer Research, 14(5 A), 1703-1709.

Urinary gonadotropin peptide (UGP) as a marker of gynecologic malignancies. / Walker, R.; Crebbin, V.; Stern, J.; Scudder, Sidney A; Schwartz, P.

In: Anticancer Research, Vol. 14, No. 5 A, 1994, p. 1703-1709.

Research output: Contribution to journalArticle

Walker, R, Crebbin, V, Stern, J, Scudder, SA & Schwartz, P 1994, 'Urinary gonadotropin peptide (UGP) as a marker of gynecologic malignancies', Anticancer Research, vol. 14, no. 5 A, pp. 1703-1709.
Walker, R. ; Crebbin, V. ; Stern, J. ; Scudder, Sidney A ; Schwartz, P. / Urinary gonadotropin peptide (UGP) as a marker of gynecologic malignancies. In: Anticancer Research. 1994 ; Vol. 14, No. 5 A. pp. 1703-1709.
@article{9efdbb54a79c44bd81034d0c12adac5d,
title = "Urinary gonadotropin peptide (UGP) as a marker of gynecologic malignancies",
abstract = "Urinary gonadotropin peptide (UGP) was measured in 866 urines from normal women and women with benign and malignant gynecologic disease using the Triton UGP enzyme immunoassay. The greatest level of overexpression of the marker was observed in patients with ovarian cancer. Using a cutoff of 4 fmol/mg creatinine, UGP was overexpressed in samples from 2{\%} of normal premenopausal women, 15{\%} of normal postmenopausal women, 5{\%} of women with benign gynecologic disease, and 59{\%} of women with ovarian cancer. UGP expression was independent of the histologic type of ovarian cancer. The expression of UGP and CA 125 were not correlated and use of the two markers in tandem increased the sensitivity of detection of disease by greater than 20{\%} over that which was observed using each marker individually. UGP levels were correlated with clinical status, and doubled in value in 67{\%} of patients with progressive disease, and were halved in 93{\%} of patients who were in remission at the time of the study.",
keywords = "CA 125, Ovarian cancer, Tumor marker, UGP, Urine",
author = "R. Walker and V. Crebbin and J. Stern and Scudder, {Sidney A} and P. Schwartz",
year = "1994",
language = "English (US)",
volume = "14",
pages = "1703--1709",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5 A",

}

TY - JOUR

T1 - Urinary gonadotropin peptide (UGP) as a marker of gynecologic malignancies

AU - Walker, R.

AU - Crebbin, V.

AU - Stern, J.

AU - Scudder, Sidney A

AU - Schwartz, P.

PY - 1994

Y1 - 1994

N2 - Urinary gonadotropin peptide (UGP) was measured in 866 urines from normal women and women with benign and malignant gynecologic disease using the Triton UGP enzyme immunoassay. The greatest level of overexpression of the marker was observed in patients with ovarian cancer. Using a cutoff of 4 fmol/mg creatinine, UGP was overexpressed in samples from 2% of normal premenopausal women, 15% of normal postmenopausal women, 5% of women with benign gynecologic disease, and 59% of women with ovarian cancer. UGP expression was independent of the histologic type of ovarian cancer. The expression of UGP and CA 125 were not correlated and use of the two markers in tandem increased the sensitivity of detection of disease by greater than 20% over that which was observed using each marker individually. UGP levels were correlated with clinical status, and doubled in value in 67% of patients with progressive disease, and were halved in 93% of patients who were in remission at the time of the study.

AB - Urinary gonadotropin peptide (UGP) was measured in 866 urines from normal women and women with benign and malignant gynecologic disease using the Triton UGP enzyme immunoassay. The greatest level of overexpression of the marker was observed in patients with ovarian cancer. Using a cutoff of 4 fmol/mg creatinine, UGP was overexpressed in samples from 2% of normal premenopausal women, 15% of normal postmenopausal women, 5% of women with benign gynecologic disease, and 59% of women with ovarian cancer. UGP expression was independent of the histologic type of ovarian cancer. The expression of UGP and CA 125 were not correlated and use of the two markers in tandem increased the sensitivity of detection of disease by greater than 20% over that which was observed using each marker individually. UGP levels were correlated with clinical status, and doubled in value in 67% of patients with progressive disease, and were halved in 93% of patients who were in remission at the time of the study.

KW - CA 125

KW - Ovarian cancer

KW - Tumor marker

KW - UGP

KW - Urine

UR - http://www.scopus.com/inward/record.url?scp=0028577764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028577764&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 1703

EP - 1709

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5 A

ER -